- Home
- YMAT vs CLRB Comparison
YMAT vs CLRB Comparison
Compare YMAT & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAT
- CLRB
- Stock Information
- Founded
- YMAT 1970
- CLRB 2002
- Country
- YMAT Taiwan
- CLRB United States
- Employees
- YMAT N/A
- CLRB N/A
- Industry
- YMAT Recreational Games/Products/Toys
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- YMAT Consumer Discretionary
- CLRB Health Care
- Exchange
- YMAT Nasdaq
- CLRB Nasdaq
- Market Cap
- YMAT 15.3M
- CLRB 12.8M
- IPO Year
- YMAT 2025
- CLRB N/A
- Fundamental
- Price
- YMAT $0.81
- CLRB $2.97
- Analyst Decision
- YMAT
- CLRB Hold
- Analyst Count
- YMAT 0
- CLRB 2
- Target Price
- YMAT N/A
- CLRB N/A
- AVG Volume (30 Days)
- YMAT 1.9M
- CLRB 310.2K
- Earning Date
- YMAT 04-29-2026
- CLRB 11-13-2025
- Dividend Yield
- YMAT N/A
- CLRB N/A
- EPS Growth
- YMAT N/A
- CLRB N/A
- EPS
- YMAT 0.07
- CLRB N/A
- Revenue
- YMAT $17,563,985.00
- CLRB N/A
- Revenue This Year
- YMAT N/A
- CLRB N/A
- Revenue Next Year
- YMAT N/A
- CLRB N/A
- P/E Ratio
- YMAT $11.86
- CLRB N/A
- Revenue Growth
- YMAT N/A
- CLRB N/A
- 52 Week Low
- YMAT $0.79
- CLRB $2.84
- 52 Week High
- YMAT $6.45
- CLRB $63.30
- Technical
- Relative Strength Index (RSI)
- YMAT N/A
- CLRB 29.64
- Support Level
- YMAT N/A
- CLRB $3.17
- Resistance Level
- YMAT N/A
- CLRB $3.72
- Average True Range (ATR)
- YMAT 0.00
- CLRB 0.25
- MACD
- YMAT 0.00
- CLRB 0.00
- Stochastic Oscillator
- YMAT 0.00
- CLRB 7.95
About YMAT J-Star Holding Co. Ltd. Ordinary Shares
J Star Holding Co Ltd is engaged in the research, development and manufacturing of carbon fiber for a wide variety of products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.